Stephen Chang, Ph.D., Director of Research. Co-Chair Scientific Advisory Board
Dr. Chang is Director of Research OneMedMarket. He brings a distinguished track record in science and business. Prior to joining OneMed Steve was the Vice President for Research and Development at The New York Stem Cell Foundation, Dr. Stephen Chang has overall responsibility for planning, coordinating, and managing the activities of the research department. In this role, he provides senior leadership in the areas of research and development, oversight of short and long term projects with regulations and policies related to administration and business units, partnerships with industry and other research institutions, and monitoring and evaluation of projects. Prior to joining NYSCF, Dr. Chang served as Chief Scientific Officer of Stemgent upon the company's founding in 2008. He was previously the CEO of Multicell Technologies and continues as a director of this company. Dr. Chang is president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative lifesaving medications. He is also a board member of Histogen, Inc., a privately held company in regenerative medicine. Dr. Chang received his PhD in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine. Areas of research interest include translational applications of basic science to pharmaceutical products.
Jonathan Steinberger, M.D., Co-Chair Scientific Advisory Board
Jonathan Steinberger MD has had over 15 years of experience working in both clinical medicine and industry. Currently an Assistant Professor of Vascular and Interventional Radiology at the Dotter Interventional Institute of Oregon Health and Science University, Jonathan worked for several years as a strategy healthcare consultant with Easton Associates (now Navigant Health), during which time he worked with various medical device, pharmaceutical, and biotech companies, including startups and large multinational corporations. He is a recent graduate of the Stanford Biodesign Innovation Fellowship program, and a cofounder of Madorra, a startup wearable technology company that is developing a treatment for vaginal atrophy. While at Biodesign, he had the opportunity to work at Orbimed Israel, working on strategy projects for medical device companies and building relationships with prominent Israeli academics. Jonathan completed vascular and interventional radiology fellowship at the David Geffen School of Medicine at UCLA, where he was a mentor at the UCLA Business of Science Center. Dr. Steinberger is co-chair of the OneMedMarket Scientific Advisory Board.
Denise Barbut, M.D., M.R.C.P., Scientific Advisor
Dr. Barbut was brought up in Istanbul, Turkey. She trained as an internist and subsequently as a neurologist in Great Britain and the USA. She received her bachelor’s degree from University College London and her Medical Degree from University College Hospital. She did her post-graduate training at Imperial College, the Royal Brompton Hospital and the National Hospital for Nervous Diseases, Queens’ Square. She is a Member of the Royal College of Physicians of the United Kingdom. She completed her neurologic training at Weill-Cornell Medical School and Memorial Sloan-Kettering Cancer Center and did a fellowship at Weill-Cornell Medical Center. Subsequently she became an Attending Physician and Professor of Neurology at Weill-Cornell Medical Center where she headed the Neurovascular Division and the Stroke Research Program. She left academia in 2000 after founding the second of her 7 biotechnology companies. Dr. Barbut is sole author or lead author on close to 200 issued or pending patents, mostly relating to methods for neuroprotection, hypothermia, the treatment of cerebral ischemia, pain and neuromodulation. She is also the lead or senior author on over 50 articles. She has been involved in founding, funding and running biotech companies for 17 years. The first two of her companies are sold, the third is going public and the remainder are at earlier stages of development. Her main interest is neurologic disorders. She is currently Founder, Board Chair and President at Sarentis Therapeutics. She is on the boards of Astuce, Novo Biosciences and Israel Brain Technologies and an advisor to Serpin Pharmaceuticals.
Michael J. Weickert, Ph.D., Scientific Advisor
Michael Weickert has extensive experience as a CEO (7 yrs; Sonescence, SEA Medical) and entrepreneurial leader (CBO, VP) in biotechnology (Somatogen), drug delivery (Inhale, Nektar, Strategent Life Sciences, Corium, Sonescence, SciDose LLC), medical devices (SEA Medical) and pharmaceuticals (Ligand, Auspex), including raising capital, establishing and maintaining business partnerships, and leading new ventures. He personally initiated and negotiated investment rounds (Seed through Series C) and partnerships worth more than $175 Million. Michael prepared dozens of business plans and marketed programs to partners in the US and internationally (Japan, Germany, United Kingdom, Switzerland, Italy, and Israel). He has driven pharmaceutical product development through all clinical phases and engaged with the FDA and EMEA on regulatory requirements, Orphan Drug and Fast Track designations. He created an anti-infectives business unit for Nektar that placed four products in development and formed the core of the $115M pulmonary business acquisition by Novartis in 2008. At Wit Creek Partners, Dr. Weickert has prepared business and marketing plans for a Nobel Prize winner’s startup and several other Venture-backed startups and for public companies, and led development of pharmaceutical and drug delivery products. Dr. Weickert is currently an advisor for several companies and served on the screening committee for Devices and for Therapeutics for 7 years with Life Science Angels, a premier Angel group in the Bay area. Dr. Weickert received his Ph.D. in Genetics from the University of Wisconsin and worked at the National Cancer Institute of NIH. He holds numerous biotechnology and device patents and published many scientific papers in leading journals.
Daniel Bertholet, Advisor
Investment Director, Endeavour Vision, Geneva, Switzerland
Daniel Bertholet is an Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in Symetis, CeQur, Endoart (sold to Allergan), Thommen Medical (exited), Kuros Biosurgery, Novalar Pharmaceuticals and Neocutis. He also participated in investments and/or follow-on investments in Native Networks, eProject/Daptiv, Paion, Nexx Systems and Novimmune. Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 15 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland.
James Huang, Advisor
Managing Partner, Kleiner Perkins Caufield & Byers China, Shanghai, China. James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. While at Vivo, James led numerous investments in China. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
Misha Petkevich, Advisor
Co-Founder & Co-Managing Partner, BladeRock Capital, LLC. BladeRock Capital, Boston, USJ
Misha Petkevich is co-founder and co-managing partner of BladeRock Capital, LLC. BladeRock Capital was formed in 2006 and currently manages the V2M® Life Sciences fund. Prior to founding BladeRock, Mr. Petkevich was Chairman and Chief Executive Officer of The Petkevich Group, LLC, a boutique merchant bank serving and investing in information technology and healthcare companies. From 1989 until 1997, Mr. Petkevich was a Managing Director at Robertson, Stephens & Co. During that time, he held various positions including Head of Investment Banking, Head of Healthcare Banking, and a member of the Management Committee, the Commitment Committee and the Fairness Opinion Review Committee. Prior to Robertson Stephens, he held positions as an Institutional Investor ranked securities analyst and as an investment banker at Hambrecht & Quist and worked closely with the life sciences venture group. Throughout his career on Wall Street, Mr. Petkevich executed directly or managed other bankers on nearly 700 financing and merger and acquisition transactions with a value of over $65 billion. Prior to Wall Street, he served as a color commentator for CBS, NBC, and ESPN. He is currently on the Board of Trustees of the United States Figure Skating Foundation and the Friends of the King Hussein Institute for Biotechnology and Cancer and is on the Advisory Board of the Gladstone Institute. Mr. Petkevich received an AB degree from Harvard College, attended Oxford University as a Rhodes Scholar where he was awarded a Doctorate in Cell Biology. While at Harvard, he created “An Evening with Champions” in 1970, a skating exhibition in which world class skaters performed and which Harvard students organized to raise money for the Dana Farber Cancer Research Foundation. 2010 represented the 40th Anniversary of the event. Following Oxford, Mr. Petkevich studied music privately, was a Fellow in the Music Department at Harvard and was Composer in Residence at Eliot House, Harvard University where some of his compositions were premiered. He represented the United States in the 1968 and 1972 Winter Olympics and was United States, North American, and World University Games Figure Skating Champion. Mr. Petkevich has been inducted in the USFSA Hall of Fame and has written two books on figure skating.
Andy Rink, M.D., Advisor
Co-founder and CMO of Lully, a company developing smart consumer products to improve sleep in kids. Andy is a Physician trained at Northwestern University and he completed the Biodesign fellowship at Stanford University. There, he worked with the world leading Stanford University Sleep Center to develop the Lully Sleep Guardian - the first device proven to stop night terrors. He also designed and completed a first-of-its-kind scientific study uncovering new discoveries in sleep. He has received multiple national grants for his research and has published in leading medical journals. Andy served on the Board of the Stanford Biodesign Alumni Association and is a regularly invited speaker at Stanford University in the areas of kid’s sleep and innovation.
Gabriella Rosen Kellerman, M.D., Advisor
Gabriella Rosen Kellerman is the founding CEO of LifeLink. Lifelink is the first
global telemedicine platform connecting patients around the world with a true
marketplace of expertise including US, Indian, and Middle Eastern doctors and
institutions. Dr. Kellerman has pioneered innovations at healthcare technology firms for the last decade, with a focus on improving patient access to care. She’s held previous leadership positions at Castlight Health and others. Prior to that, she was a practicing physician and neuroimaging researcher, with expertise in autism and neuropsychiatry.
Akhilesh Sista, M.D., Advisor
Dr. Sista specializes in the endovascular treatment of venous thromboembolic disease (VTE). He is the Section Chief of the NYU-Langone Division of Vascular and Interventional Radiology and has a busy clinical inpatient and outpatient practice. He has significant experience with the morbidity and challenges associated with deep venous thrombosis (DVT) and pulmonary embolism (PE). He is recognized as a clinical expert in VTE, having given numerous invited talks at international meetings on the topic and served on national committees. He has authored or co-authored >30 peer-reviewed publications, including clinical practice standards in the medical and radiologic literature. As the site Principal Investigator for the ATTRACT trial, the PERFECT registry and Principal Investigator of the RESPECT pulmonary embolism registry, he is involved in national and local research looking into improving outcomes for patients with VTE. His research is also translational, as he received grant funding from the Radiologic Society of North America to investigate the physiologic consequences of submassive pulmonary embolism in a porcine model with an eye towards optimizing the safety and efficacy of catheter-directed therapy for submassive PE patients. He recently chaired a multi-disciplinary expert consensus panel, sponsored by the Society of Interventional Radiology Foundation, tasked with identifying research priorities for submassive pulmonary embolism. He was also a Stanford Biodesign Fellow from 2009-2010 and taught several courses on Biodesign to medical and graduate students.
Dennis J. Purcell, Advisor
Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.
Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry. Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member. Mr. Purcell received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware.
The advisors to OneMedMarket which includes a wide range of perspectives from those experienced in building and financing healthcare and life science companies. It is comprised of active fund managers, strategic investors, clinical experts, scientists, entrepreneurs, executives, physicians, executives and key opinion leaders.
World class advisory board delivers unique insights.